Quest Diagnostics (DGX)
(Delayed Data from NYSE)
$142.34 USD
-0.30 (-0.21%)
Updated Jun 7, 2024 04:00 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DGX 142.34 -0.30(-0.21%)
Will DGX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for DGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DGX
Take the Zacks Approach to Beat the Markets: Robinhood Markets, Victory Capital, NVIDIA in Focus
Why Is Amedisys (AMED) Up 5.5% Since Last Earnings Report?
DGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Quest Diagnostics (DGX) Up 3.1% Since Last Earnings Report?
Take the Zacks Approach to Beat the Markets: Goldman Sachs, Rush Street Interactive, Atmus Filtration Technologies in Focus
Quest Diagnostics (DGX) Grows in Digital Pathology With New Deal
Other News for DGX
Lab Week 2024 - Lisa Szeto-Tay
Quest Diagnostics Grows Interest in Sustainability With Healthy NewsWorks Students
Blood-based MRD Test for Cancer Recurrence Can Generate Cost Savings in Colorectal Cancer Treatment, Finds Study in JAMA Health Forum
Quest Diagnostics price target raised by $3 at JPMorgan, here's why
Analyst Scoreboard: 7 Ratings For Quest Diagnostics